Vitamin E in front line of prostate cancer fight
Survival rates of prostate cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth.
Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3,000 Australian men a year.
Dr Patrick Ling, whose research will be a centrepiece of the new $354 million Translational Research Institute (TRI) when it opens in Brisbane, is leading a team of researchers who have identified a particular constituent of vitamin E, known as tocotrienol (T3), which can inhibit the growth of prostate tumours.
Construction of the TRI officially began on 19 October at the Princess Alexandra Hospital. The world-class facility brings together some of Queensland’s best medical researchers from four leading Australian research facilities to turn their work into accessible and potentially life-saving health treatments.
